FGF401,
Roblitinib,
1708971-55-4,
FGF-401,
UNII-M64JF6WMSA,
M64JF6WMSA,
N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide,
N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide,
N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-carboxamide,
Roblitinib [INN],
Roblitinib (FGF401),
NVP-FGF401,
GTPL9768,
CHEMBL3908979,
FGF 401 [WHO-DD],
SCHEMBL16668840,
BHKDKKZMPODMIQ-UHFFFAOYSA-N,
BDBM209325,
BCP25143,
EX-A1341,
Example 83 [US9266883],
AKOS032946374,
ZINC644165879,
ACN-051242,
CS-6853,
AC-29896,
AK687571,
HY-101568,
US9266883, 83,
N-{5-cyano-4-[(2-methoxyethyl)amino]pyridin-2-yl}-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-1,2,3,4-tetrahydro-1,8-naphthyridine-1-carboxamide,